Table 2.

Multivariate logistic regression analysis for the achievement of low disease activity (LDA), clinical remission, and moderate or good EULAR response at 24 weeks in the overall patients using abatacept (upper column) or in the patients with high disease activity at baseline using abatacept, adalimumab, or tocilizumab (lower column)

	LDA at 24 weeks		Remission at 24 weeks		Moderate or good EULAR response at 24 weeks
	Adjusted OR (95 % CI)	p value	Adjusted OR (95% CI)	p value	Adjusted OR (95% CI)	p value
Overall patients taking abatacept
DAS28-CRP > 4.1	0.261 (0.135–0.503)	<0.001	0.264 (0.124–0.564)	0.001	3.010 (1.626–5.574)	<0.001
Steinbrocker class 1–2 (vears 3–4)	2.427 (1.145–5.147)	0.021	2.003 (0.853–4.707)	0.111	1.670 (0.841–3.318)	0.143
No previous use of biologics	2.346 (1.185–4.642)	0.014	2.056 (0.938–4.508)	0.072	2.824 (1.520–5.250)	0.001
Concomitant MTX use	0.698 (0.353–1.381)	0.302	0.652 (0.299–1.425)	0.284	0.798 (0.433–1.472)	0.47
Patients with HDA at baseline
Adalimumab use (vs abatacept)	1.361 (0.683–2.711)	0.381	1.611 (0.712–3.648)	0.252	0.740 (0.402–1.363)	0.334
Tocilizumab use (vs abatacept)	1.479 (0.733–2.983)	0.275	1.057 (0.430–2.598)	0.904	2.594 (1.316–5.114)	0.006
DAS28-CRP score at baseline	0.768 ( 0.551–1.070)	0.119	0.600 (0.386–0.933)	0.023	0.929 (0.700–1.232)	0.608
Steinbrocker class 1–2 (vears 3–4)	2.809 (1.570–5.029)	0.001	3.254 (1.509–7.019)	0.003	1.830 (1.119–2.994)	0.016
No previous use of biologics	2.030 (1.187–3.473)	0.01	3.070 (1.558–6.049)	0.001	2.152 (1.299–3.567)	0.003
Concomitant MTX use	0.934 (0.522–1.672)	0.818	1.102 (0.543–2.237)	0.788	1.157 (0.676–1.982)	0.594

OR odds ratio, CI confidence interval, EULAR European League Against Rheumatism, DAS28 Disease Activity Score in 28 joints, MTX methotrexate